RNA therapeutics and epitranscriptomics are emerging as key areas in medicine, offering transient and precise modulation of gene expression with less arduous regulatory pathways. Platforms such as Korro Bio’s OPERA enable targeted RNA editing through ADAR enzymes, optimizing dosage and minimizing off-target effects. Meanwhile, global initiatives funded by Novo Nordisk aim to establish protein design centers to accelerate engineered protein development for applications ranging from therapeutics to environmental uses, complementing AI-driven drug discovery approaches.